Pharmacologic Therapy for Mitral Valve Prolapse
Most patients with uncomplicated mitral valve prolapse (MVP) require no pharmacologic therapy beyond reassurance, as the condition is generally benign in the absence of significant mitral regurgitation or arrhythmic complications.
When Medication IS Indicated
Beta-Blockers for Symptomatic Management
Beta-blockers are the first-line pharmacologic treatment for symptomatic MVP patients with disabling chest pain, palpitations, or documented arrhythmias 1, 2, 3. The evidence shows:
- Metoprolol demonstrates remarkable efficacy for palpitations and cardiac arrhythmias on ambulatory ECG monitoring 2
- Beta-blockers with intrinsic sympathomimetic activity (ISA) like pindolol may be preferable, as they avoid the significant decreases in heart rate, left ventricular ejection fraction, and peak systolic emptying velocity seen with propranolol 1
- These agents are effective for symptomatic management but do NOT prevent progression of mitral regurgitation or reduce sudden death risk 4
Antiplatelet Therapy
Antiplatelet therapy may be indicated for patients with documented cerebral embolic events 3, though this represents a rare complication of MVP.
Antiarrhythmic Therapy
For patients with complex ventricular arrhythmias refractory to beta-blockers, specialized antiarrhythmic agents may be considered 5. However, this requires careful risk stratification and typically specialist management.
When Medication is NOT Indicated
The majority of MVP patients—particularly those with isolated prolapse, no significant mitral regurgitation, and normal left ventricular function—require no treatment 4, 3. This includes:
- Asymptomatic patients with mild MVP
- Patients with atypical chest pain without objective documentation of arrhythmias
- Patients with palpitations unconfirmed by ambulatory monitoring
Critical Caveats
The Arrhythmic MVP Syndrome
A subset of MVP patients are at risk for sudden cardiac death (arrhythmic MVP or A-MVP syndrome) 6, 7. High-risk features include:
- Mitral annular disjunction on echocardiography
- Fibrosis on cardiac MRI (particularly in papillary muscles)
- ST-segment depression, T-wave inversion, or biphasic T waves in inferior leads
- Premature ventricular contractions arising from papillary muscles
- Left ventricular end-systolic diameter ≥40 mm 8
Patients with these high-risk features should be referred for specialized evaluation 7, as they may require ICD placement rather than simple medical management. Beta-blockers have NOT been proven to reduce sudden death risk in this population 4.
Exercise Restrictions
If any arrhythmic risk markers are present, patients should refrain from high-intensity exercise 9. Otherwise, most MVP patients can engage in normal physical activity.
What Does NOT Work
There are currently no evidence-based pharmacologic interventions to prevent progression of mitral regurgitation, reduce stroke risk, or prevent endocarditis in MVP patients 4. The focus remains on symptomatic management and identifying those who need surgical intervention rather than medical therapy.